PRGO

MKT CAP:$2B

Perrigo Company plc

Market Cap

$2B

Healthcare·Drug Manufacturers - Specialty & Generic·🇮🇪 Ireland·NYSE

Healthcare·Drug·🇮🇪·NYSE

Stock Price

$11.69-$2.20 (-15.84%)

Apr 23, 2026

Company Details

Perrigo Company plc provides over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to prevent or treat conditions that can be self-managed. The company operates through two segments,...

CEO

Patrick Lockwood-Taylor

IPO Date

Dec 17, 1991

Website

www.perrigo.com

Key Metrics TTM

Revenue

$4.4B

-3.4% YoY

Net Income

-$1.6B

EPS (Diluted)

-$11.47

Free Cash Flow

$420M

Revenue / Share

$31.78

Gross Margin

35.2%

Operating Margin

5.7%

Net Margin

-36.2%

FCF Margin

9.5%

P/S

0.4x

P/E

—

Earnings Reports

Q1 2026

May 6, 2026

PENDING

Q4 2025

Feb 26, 2026

$1.1B-2.5%EPS -$10.23

FY 2024

Feb 28, 2025

$4.4B-6.1%EPS -$1.25

Q4 2024

Feb 28, 2025

$1.1B-1.6%EPS -$0.32

Q3 2024

Nov 6, 2024

$1.1B-3.2%EPS -$0.15

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q3 20	$1.0B	$370M	$79M
Q4 20	$1.3B	$469M	-$52M
Q1 21	$1.0B	$368M	$51M
Q3 21	$1.0B	$336M	$438M
Q2 22	$1.1B	$372M	-$7M
Q3 22	$1.1B	$363M	$33M
Q4 22	$1.2B	$383M	$31M
Q1 23	$1.2B	$414M	$49M
Q2 23	$1.2B	$428M	$57M
Q3 23	$1.1B	$411M	$62M
Q4 23	$1.2B	$427M	-$16M
Q1 24	$1.1B	$358M	-$55M
Q2 24	$1.1B	$395M	-$27M
Q3 24	$1.1B	$404M	$80M
Q4 24	$1.1B	$386M	$114M
Q4 25	$1.1B	$362M	$85M

Valuation

Quarter	P/S	P/E
Q3 20	0.3x	—
Q4 20	0.3x	—
Q1 21	0.4x	—
Q3 21	0.4x	—
Q2 22	0.4x	—
Q3 22	0.4x	—
Q4 22	0.4x	—
Q1 23	0.4x	—
Q2 23	0.4x	—
Q3 23	0.4x	—
Q4 23	0.4x	—
Q1 24	0.4x	—
Q2 24	0.4x	—
Q3 24	0.4x	—
Q4 24	0.4x	—
Q4 25	0.4x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q3 20	$63M	$19M
Q4 20	$110M	$44M
Q1 21	$200.0K	-$45M
Q3 21	$344M	$302M
Q2 22	-$17M	-$55M
Q3 22	$59M	$38M
Q4 22	$186M	$160M
Q1 23	$19M	-$4M
Q2 23	$53M	$33M
Q3 23	$125M	$93M
Q4 23	$209M	$182M
Q1 24	-$1M	-$27M
Q2 24	$10M	-$19M
Q3 24	$42M	$15M
Q4 24	$313M	$275M
Q4 25	$175M	$149M

Capital Expenditures

Quarter	CapEx
Q3 20	$44M
Q4 20	$66M
Q1 21	$45M
Q3 21	$42M
Q2 22	$38M
Q3 22	$21M
Q4 22	$26M
Q1 23	$23M
Q2 23	$20M
Q3 23	$32M
Q4 23	$27M
Q1 24	$25M
Q2 24	$28M
Q3 24	$27M
Q4 24	$38M
Q4 25	$27M

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q3 20	-14.6%	-13.8%
Q4 20	+12.2%	+22.6%
Q1 21	-15.2%	-15.7%
Q3 21	-21.2%	-54.5%
Q2 22	+11.8%	+22.1%
Q3 22	-14.7%	-20.5%
Q4 22	+14.4%	+17.3%
Q1 23	+13.3%	+87.5%
Q2 23	+6.4%	+0.7%
Q3 23	+2.1%	-0.5%
Q4 23	+0.1%	+4.3%
Q1 24	-8.4%	+0.4%
Q2 24	-10.7%	-3.9%
Q3 24	-3.2%	-5.1%
Q4 24	-1.6%	-12.7%
Q4 25	+2.5%	-9.9%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q3 20	$14M	1.4%
Q4 20	$15M	1.1%
Q1 21	$25M	2.5%
Q3 21	$11M	1.1%
Q2 22	$0	0.0%
Q3 22	$9M	0.9%
Q4 22	$8M	0.7%
Q1 23	$25M	2.1%
Q2 23	$19M	1.6%
Q3 23	$15M	1.3%
Q4 23	$11M	0.9%
Q1 24	$16M	1.4%
Q2 24	$23M	2.2%
Q3 24	$6M	0.5%
Q4 24	$20M	1.7%
Q4 25	$0	0.0%

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q3 20	$30M	$111M	$153M
Q4 20	$46M	$138M	$192M
Q1 21	$31M	$127M	$157M
Q3 21	$28M	$131M	$153M
Q2 22	$32M	$158M	$180M
Q3 22	$30M	$106M	$175M
Q4 22	$33M	$126M	$182M
Q1 23	$31M	$135M	$197M
Q2 23	$32M	$133M	$200M
Q3 23	$30M	$126M	$178M
Q4 23	$30M	$129M	$178M
Q1 24	$29M	$130M	$175M
Q2 24	$29M	$126M	$175M
Q3 24	$26M	$117M	$155M
Q4 24	$28M	$95M	$140M
Q4 25	$22M	—	$70M

Revenue Segments

Quarter	Consumer Self-Care Americas	Consumer Self-Care International	RX Pharmaceuticals
Q4 20	$701M	$352M	$236M
Q1 21	$641M	$370M	—
Q3 21	$694M	$349M	—
Q2 22	$728M	$394M	—
Q3 22	$722M	$378M	—
Q4 22	$766M	$390M	—
Q1 23	$764M	$418M	—
Q2 23	$751M	$442M	—
Q3 23	$704M	$420M	—
Q4 23	$744M	$413M	—
Q1 24	$644M	$438M	—
Q2 24	$634M	$431M	—
Q3 24	$671M	$416M	—
Q4 24	$744M	$394M	—
Q4 25	$697M	$413M	—

Revenue by Geography

Quarter	Europe	Ireland	Other Geographical Areas	United States
Q4 20	$340M	$7M	$80M	$870M
Q1 21	$355M	$5M	$43M	$611M
Q3 21	$335M	$8M	$51M	$657M
Q2 22	$382M	$7M	$22M	$718M
Q3 22	$365M	$6M	$19M	$716M
Q4 22	$376M	$9M	$26M	$753M
Q1 23	$407M	$7M	$24M	$750M
Q2 23	$426M	$12M	$32M	$736M
Q3 23	$400M	$12M	$34M	$690M
Q4 23	$390M	$10M	$27M	$741M
Q1 24	$420M	$4M	$30M	$632M
Q2 24	$408M	$11M	$29M	$628M
Q3 24	$397M	$11M	$33M	$657M
Q4 24	$379M	$13M	$27M	$732M
Q4 25	$398M	$13M	$27M	$685M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$2.0B	$0	$2.0B
Q2 22	$485M	$0	$485M
Q3 22	$469M	$0	$469M
Q4 22	$601M	$0	$601M
Q1 23	$553M	$0	$553M
Q2 23	$555M	$0	$555M
Q3 23	$598M	$0	$598M
Q4 23	$751M	$0	$751M
Q1 24	$652M	$0	$652M
Q2 24	$538M	$0	$538M
Q3 24	$1.5B	$0	$1.5B
Q4 24	$559M	$0	$559M
Q1 25	$410M	$0	$410M
Q2 25	$454M	$0	$454M
Q3 25	$432M	$0	$432M
Q4 25	$532M	$0	$532M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q3 20	138M	+0.2%	+1.0%
Q4 20	136M	-1.2%	-0.4%
Q1 21	135M	-1.0%	-1.6%
Q3 21	134M	-0.6%	-2.5%
Q2 22	135M	+0.6%	-2.2%
Q3 22	135M	0.0%	-1.0%
Q4 22	135M	+0.1%	+0.1%
Q1 23	135M	+0.1%	+0.8%
Q2 23	137M	+1.3%	+1.5%
Q3 23	137M	+0.2%	+1.7%
Q4 23	136M	-1.0%	+0.6%
Q1 24	138M	+1.5%	+2.0%
Q2 24	137M	-0.4%	+0.4%
Q3 24	138M	+0.3%	+0.4%
Q4 24	138M	+0.1%	+1.5%
Q4 25	139M	+0.7%	+0.7%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q3 20	$89.6K	11K
Q4 20	$112.1K	12K
Q1 21	$87.8K	12K
Q3 21	$90.7K	12K
Q2 22	$113.3K	10K
Q3 22	$111.1K	10K
Q4 22	$129.8K	9K
Q1 23	$132.8K	9K
Q2 23	$134.1K	9K
Q3 23	$126.3K	9K
Q4 23	$126.6K	9K
Q1 24	$118.4K	9K
Q2 24	$116.6K	9K
Q3 24	$119.0K	9K
Q4 24	$135.9K	8K
Q4 25	$137.0K	8K

Revenue / Employee